Deltex Medical Group plc
DTXMF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | 0.03 | 0.00 | -1.00 |
| FCF Yield | -10.78% | -129.58% | -29.78% | -7.26% |
| EV / EBITDA | -7.82 | -2.64 | -7.41 | -20.53 |
| Quality | ||||
| ROIC | -44.75% | -20.49% | -20.91% | -20.06% |
| Gross Margin | 68.00% | 63.34% | 74.09% | 69.72% |
| Cash Conversion Ratio | 0.27 | 0.93 | 0.53 | 0.30 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.08% | -7.71% | 1.15% | -19.03% |
| Free Cash Flow Growth | 68.69% | -15.93% | -44.39% | -291.21% |
| Safety | ||||
| Net Debt / EBITDA | -2.19 | -1.32 | -1.87 | -1.91 |
| Interest Coverage | 0.00 | -4.57 | -4.76 | -4.65 |
| Efficiency | ||||
| Inventory Turnover | 1.08 | 0.91 | 0.78 | 0.86 |
| Cash Conversion Cycle | 252.33 | 341.23 | 250.45 | 339.75 |